Transient lupus anticoagulants associated with hemorrhage rather than thrombosis: the hemorrhagic lupus anticoagulant syndrome.
Lupus anticoagulants (LAs) represent a diverse group of antibodies directed against phospholipids. Patients with LAs may be free of symptoms but can have thrombotic complications including stroke, placental infarction, and fetal loss. Rarely hemorrhagic symptoms have been reported. We describe six previously healthy children who were first seen with clinical bleeding and prolonged activated partial thromboplastin time. Laboratory evaluation revealed positive results on mixing studies and evidence of phospholipid dependence of the anticoagulant, suggesting LAs. Four of six patients had anticardiolipin antibodies, and all four who were tested had reduced factor II activity levels. In all patients, bleeding symptoms resolved spontaneously within 3 months, and laboratory findings returned to normal within 6 months. The hemorrhagic LA syndrome should be considered in previously healthy children with new-onset bleeding and prolonged activated partial thromboplastin time. This clinical entity probably represents pathogenic mechanism distinct from thrombotic LA syndromes.
Becton
D L
DL
Department of Pediatrics, University of Medical Sciences and Arkansas Children's Hospital, Little Rock, USA.
Stine
K C
KC
D001921:Brain / Q000503:physiopathology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006470:Hemorrhage / Q000503:physiopathology*; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic; D008297:Male; D010314:Partial Thromboplastin Time; D010743:Phospholipids / Q000276:immunology; D011517:Prothrombin Time; D013577:Syndrome; D013927:Thrombosis
D016682:Lupus Coagulation Inhibitor; D010743:Phospholipids